Dublin, Jan. 24, 2018 (GLOBE NEWSWIRE) -- The "Market Spotlight: Mesothelioma" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the mesothelioma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The author estimates that in 2016, there were 18,370 incident cases of mesothelioma in adults aged 45 years and older worldwide, and forecasts that number to increase to 22,170 incident cases by 2025.
  • Oceania is estimated to have the highest disease incidence (2.85 per 100,000 males, and 0.50 per 100,000 females), while Latin America and the Caribbean has the lowest incidence (0.29 per 100,000 males, and 0.17 per 100,000 females).
  • The majority of industry-sponsored drugs in active clinical development for mesothelioma are in Phase II.
  • Mid-to-late-stage pipeline drugs for mesothelioma are focusing on targets such as dihydrofolate reductase, thymidylate synthase, programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), and mesothelin. Among these therapies, EP-5101, the first liquid formulation of pemetrexed, is closest to market.
  • Alimta (pemetrexed), an antifolate antineoplastic agent, is the only drug approved by the US Food and Drug Administration (FDA) for mesothelioma.
  • High impact upcoming events for drugs in the mesothelioma space include topline Phase II and Phase III trial results, as well as the FDA's decision on EP-5101's New Drug Application (NDA).
  • Licensing and asset acquisition activity involving mesothelioma drugs has been weak during 2012-17, with only four deals occurring over this time period. The $9.3m licensing agreement between Selecta Biosciences and the National Cancer Institute for the development of LMB-100 for pancreatic cancer, mesothelioma, and other cancers was the only deal with a disclosed deal value during 2012-17.
  • Clinical trial distribution across Phase I-IV indicates that the majority of drugs are in the early and mid phases of development, with 95% of trials in Phase I-II and only 5% in Phase III-IV.
  • The US has a substantial lead in the number of mesothelioma clinical trials globally, yet forecasted cases of mesothelioma are lower in North America as compared to Europe and Asia. The UK leads the major EU markets, while Japan has the top spot in Asia, where the incident cases of mesothelioma are the highest.
  • Eli Lilly is the leading company in terms of development in mesothelioma with 48 total trials; however, 41 of these trials have already been completed. AstraZeneca has the most ongoing trials with nine, followed by Merck & Co with eight.

Key Topics Covered:

1 KEY TAKEAWAYS

2 DISEASE BACKGROUND

  • Mesothelioma subtypes

3 TREATMENT

  • Surgery
  • Chemotherapy
  • Radiotherapy

4 EPIDEMIOLOGY

5 PIPELINE DRUGS

6 MARKETED DRUGS

  • Approvals by country

7 KEY UPCOMING EVENTS

8 LICENSING AND ASSET ACQUISITION DEALS

  • Selecta Licenses Next-Gen Immunotoxin From NCI
  • Merck Expands Aduro Collaboration In Keytruda Tie-Up

9 PARENT PATENTS

10 REVENUE OPPORTUNITY

11 CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

12 BIBLIOGRAPHY

  • Prescription information

13 APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/bg7jn5/global?w=12



CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Oncology Drugs

Primary Logo